Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization

Journal of Managed Care Pharmacy

Volumn 14, Issue 5, 2008, Pages 442-450

  Mitchell, Matthew P ^a   Schaecher, Kenneth ^a   Cannon, H Eric ^a   Speckman, Matt ^a  

^a Pharmacy Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CAFERGOT; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL MUSCLE RELAXANT; HYDANTOIN DERIVATIVE; ISOMETHEPTENE; MIRTAZAPINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUCCINIMIDE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; VALPROIC ACID;

ABSENTEEISM; ADULT; ARTICLE; BILLING AND CLAIMS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEMALE; HEADACHE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HOSPITAL CHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAL FEE; MIGRAINE; PHARMACY; PRODUCTIVITY; QUALITY OF LIFE; RECREATION; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TENSION HEADACHE; TREATMENT OUTCOME;

EID: 48449088011     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.5.442     Document Type: Article

References (7)

1. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM, for the U.S. Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. American Academy of Neurology. April 2000. Available at: www.aan.com/professionals/practice/pdfs/gl0090.pdf. Accessed January 12, 2008.
2. Carianne MC, Dekker F. Acceptance or rejection of prophylactic medicine patients with migraine: a cross-sectional study. Br J Gen Pract. 2008; 58(547):98-101.
3. Etemad LR, Yang W, Globe D, Barlev A, Johnson KA. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):137-44. Available at: www.amcp.org/data/jmcp/ Original%20Research-137-144.pdf.
4. Silverstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology. 2000;54(8):1553.
5. Naumann M, So Y, Argoff CE, e Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Neurology. 2008;70;1707-14.
6. Schulte-Mattler WJ, Leinisch E. Evidence-based medicine on the use of botulinum toxin for headache disorders. J Neural Transm. 2008; 115(4):647-51. PMID=17994180.
7. Cady R, Schreiber C. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache. 2008;48(6):900-13.